Development in the syllabus of Pharmaceutical Marketing & Management that is studied in the Bachelor of Pharmacy course of Bangladeshi Universities.        LOSECTIL stands beside acid survivors        Vitamin D Levels Linked to Parkinson's Symptoms        Keeping the newborn warm at home at winter        Itís time to prevent cervical cancer        Huge Rise in CT, MRI, Ultrasound Scan Use: Study        Exercise May Delay Early Aging of People With Diabetes        Alzheimer's Drug Shows Some Promise in Trials        Obesity, Depression Blamed for Daytime Sleepiness Epidemic        Fruits, Veggies May Help Smokers Quit     

Member Sign In
Forgot Your
Username & Password?


Not a Member?
Please Sign Up Here


 
 
Sr. Executive / Executive, Production; THE IBN SINA PHARMACEUTICAL IND LTD

 
Approval of Natroba Topical Suspension (spinosad) by FDA
Brand Name: Natroba Topical Suspension
Generic Name: spinosad
Company Name: ParaPRO LLC
Date of Approval: January 18, 2011
Treatmant for: Head lice infestations
The U.S. Food and Drug Administration today approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice infestation in patients ages 4 years and older.

Head lice are parasitic insects found on people's head, eyebrows, and eyelashes. They feed on human blood several times a day but are not known to cause disease. Head lice are spread mainly by direct head-to-head contact with a person who already has head lice. Lice move by crawling and can easily travel from child to child because children play closely together and often in large groups.

"Natroba provides another option for the topical treatment of head lice infestations, which are especially prevalent in the pediatric population," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDAís Center for Drug Evaluation and Research. "Head lice is a common problem among school children in the United States."

Natroba is a topical drug product and should be applied only to the childís scalp or hair. The product should be used exactly as prescribed by a health care professional.

The safety and effectiveness of Natroba Topical Suspension 0.9 %, has been established in two multicenter, randomized, active-controlled studies. A total of 552 subjects received a 10-minute treatment with Natroba. If live lice were seen a week later, a second treatment was applied. The proportion of subjects who were lice-free fourteen days after the final treatment of Natroba was approximately 86 percent compared to 44 percent of the control group.

Common adverse events reported include redness or irritation of the eyes and skin.

Safety in pediatric patients below the age of 4 years has not been established. Although Natroba is not approved for use in children younger than 4 years, it is especially important not to use in infants because the product contains benzyl alcohol. Benzyl alcohol has been associated with serious adverse reactions, including death, when applied topically to the skin of children younger than 6 months.

Natroba is manufactured for ParaPRO LLC of Carmel, Ind.
Note: To know more please go to the following sources.
Update: 2011-01-18
Source: Drugs.com & FDA
 
Other FDA Approval
Approval of Yervoy Injection (ipilimumab) by FDA
Approval of Tradjenta Tablets (linagliptin) by FDA
Approval of Juvisync Tablets (simvastatin and sitagliptin) by FDA
Approval of Daliresp Tablets (roflumilast) by FDA
Approval of Lazanda Nasal Spray (fentanyl) by FDA
Approval of Edarbi Tablets (azilsartan medoxomil) by FDA
Approval of Arcapta Neohaler (Indacaterol) by FDA
Approval of Natroba Topical Suspension (spinosad) by FDA
See all the FDA Approval